Recommendations Updated for Meningococcal Vaccine in HIV

Share this content:
Recommendations Updated for Meningococcal Vaccine in HIV
Recommendations Updated for Meningococcal Vaccine in HIV

MONDAY, Nov. 7, 2016 (HealthDay News) -- In the Nov. 4 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, new recommendations are presented for meningococcal conjugate vaccination among HIV-infected individuals.

Noting that a growing body of evidence suggests increased risk for meningococcal disease in HIV-infected individuals, Jessica R. MacNeil, M.P.H., from the CDC in Atlanta, and colleagues modified recommendations on vaccination with meningococcal conjugate vaccine.

The authors recommend that all HIV-infected individuals aged ≥2 months should receive meningococcal conjugate vaccine (serogroups A, C, W, and Y); a multi-dose schedule should be used for children aged younger than 2 years. A two-dose primary series of meningococcal conjugate vaccine is recommended for individuals aged ≥2 years. A booster dose should be given at the earliest opportunity (at least eight weeks after the previous dose) for persons with HIV who have been previously vaccinated; boosters should continue at appropriate intervals. A booster dose should be administered three years later if the most recent dose was received before age 7 years. If the most recent dose was received at age ≥7 years, a booster should be given five years later and every five years thereafter.

"The recommendations for children aged 2 months through 2 years and persons aged ≥25 years are based on expert opinion; the vaccine was not studied in HIV-infected persons in these age groups," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ATS: Cancer-Related Suicide Risk Highest for Lung Cancer Patients

ATS: Cancer-Related Suicide Risk Highest for Lung Cancer ...

Odds up four-fold compared to people in the general population

Mortality Rates Found Lower at Major Teaching Hospitals

Mortality Rates Found Lower at Major Teaching Hospitals

Researchers assessed 30-day survival for older patients

Opioid Use Before TKA May Lead to Worse Pain After Surgery

Opioid Use Before TKA May Lead to Worse ...

Researchers suggest limiting opioid prescriptions might optimize benefits of TKA

is free, fast, and customized just for you!

Already a member?

Sign In Now »